Serological Analysis of Alpha-synuclein and NF-?B in Parkinson’s Disease Patients BC01-BC04
Dr. Vineeta Gupta,
Senior Research Fellow, Department of Pharmacology and Therapeutics, King Georgeâ€™s Medical University,
Lucknow-226003, Uttar Pradesh, India.
E-mail : email@example.com
Introduction: Several investigations have been made to determine the level of alpha-synuclein in the peripheral blood of Parkinsonâ€™s disease patients, but the results were very contradictory and inconclusive. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-?B) was also found to be involved in Parkinsonâ€™s disease, but there is a lack of studies investigating NF-?B in Parkinsonâ€™s disease patients. As far as our knowledge goes, no study reported the level of NF-?B in serum of Parkinsonâ€™s disease patients. In this context, present study was designed to make a baseline study in order to evaluate the levels of total alpha-synuclein and NF-?B in serum of Parkinsonâ€™s disease patients.
Materials and Methods: Serum samples were collected from Parkinsonâ€™s disease patients (n=97) and healthy controls (n=97). Their levels were determined by using Enzyme linked immunosorbent assay.
Results: The levels of total alpha-synuclein (patients=5.79Â±2.24 ng/ml, controls=6.20Â±1.61 ng/ml; p=0.14) and NF-?B (patients=1.38Â±0.99 ng/ml, controls=1.65Â±1.00 ng/ml; p=0.71) were lower in Parkinsonâ€™s disease patients than controls, but the differences were not statistically significant. This difference was also failed to reach significance between males (alpha-synuclein (p)=0.70, NF-?B (p)=0.84) and females (alpha-synuclein (p)=0.06, NF-?B (p)=0.77) in both the groups as well as within the groups. The levels of total alpha-synuclein and NF-?B were also not associated with Parkinsonâ€™s disease severity (alpha-synuclein (p) = 0.84, NF-?B (p) = 0.73).
Conclusion: A non-significant difference in the levels of total alpha-synuclein and NF-?B between Parkinsonâ€™s disease patients and controls suggested that these are not valuable biomarkers for Parkinsonâ€™s disease, more specifically in Indian population.